Wire · opportunities
FDA Accepts Nicox's NDA for NCX 470 for Glaucoma and OIcular Hypertension
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 August 2026 · Fusion42 review
The FDA has accepted Nicox's NDA for NCX 470, a novel drug for lowering intraocular pressure in glaucoma and ocular hypertension, setting a PDUFA target date of April 30, 2027. The application is supported by positive phase 3 trial data, and a US launch is targeted in the second half of 2027 pending approval.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Your path to US market entry for a glaucoma treatment just got a clear roadmap with the FDA’s acceptance of NCX 470’s NDA. This opens the window to finalise commercial partnerships and ramp up regulatory preparations ahead of the 2027 launch.
◆ Coverage
1 source · 27 Aug 2026
◆ Related on Wire
◆ Topics